﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropathology</JournalTitle>
      <Issn>2251-8363</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2019</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of fibroblast growth factor-23 on blood pressure and pulse pressure in hemodialysis patients; a multicenter study</ArticleTitle>
    <FirstPage>e09</FirstPage>
    <LastPage>e09</LastPage>
    <ELocationID EIdType="doi">10.15171/jnp.2019.09</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Farzanehsadat</FirstName>
        <LastName>Minoo</LastName>
      </Author>
      <Author>
        <FirstName>Mahdieh</FirstName>
        <LastName>Jamshidi</LastName>
      </Author>
      <Author>
        <FirstName>Elham</FirstName>
        <LastName>Ramezanzadeh</LastName>
      </Author>
      <Author>
        <FirstName>Mohammadtaghi</FirstName>
        <LastName>Najafi</LastName>
      </Author>
      <Author>
        <FirstName>Azam</FirstName>
        <LastName>Alamdari</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jnp.2019.09</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>06</Month>
        <Day>25</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>08</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Hypertension seems to be a major problem in dialysis patients. Fibroblast growth factor-23 (FGF-23) appears to be a risk factor for mortality in patients with end-stage renal disease (ESRD). Objectives: This study aims to investigate FGF-23 and its association with blood pressure and pulse pressure among hemodialysis patients. Patients and Methods: This cross-sectional multicenter study was performed on 135 patients aged 18 years and over with ESRD treated with hemodialysis. Systolic and diastolic blood pressure of all patients was measured. FGF-23, uric acid, Na and K were measured using blood test and fasting. We used univariate and multivariate linear and non-linear regression. Results: The mean age of patients was 56.45±13.64 years. Around 60% of patients were male. The mean and median FGF-23 in patients was 855.07±43.33 pg/mL and 762.6 pg/mL (IQR=456.6-1430.3) respectively. After adjustment for age, gender, dialysis time, uric acid, Na, K and kt/V, FGF-23 had quadratic association with pulse pressure. We found, each 10-unit (pg/mL) increase in FGF-23 was significantly associated with 0.50 mm Hg decrease in minimum pulse pressure (P=0.002) and 0.42 mm Hg decrease in mean pulse pressure (P= 0.009). Conclusions: FGF23 had a significant association with dialysis vintage and a significant reverse association with minimum and mean pulse pressure.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fibroblast growth factor-23</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pulse pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hemodialysis</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>